A meta-analysis of nine randomised trials involving nearly 68,000 patients shows evolocumab dramatically lowers LDL ...
脂蛋白(a) [Lp(a)] 是动脉粥样硬化性心血管疾病（ASCVD）及钙化性主动脉瓣狭窄的致病危险因素，其水平主要由遗传因素决定，在个体内通常相对稳定。现行指南 [1] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results